Premalignant and malignant conditions of the female genital tract

Published on 10/03/2015 by admin

Filed under Obstetrics & Gynecology

Last modified 10/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3239 times

Chapter 37 Premalignant and malignant conditions of the female genital tract

Only four cancers can be either prevented or diagnosed at a stage when treatment is curative in most cases:

CERVICAL PRECANCER AND CANCER

The cervical epithelium undergoes changes throughout the menstrual cycle and is readily accessible for examination. The epithelium covering the ectocervix is stratified and identical to that of the vagina (Fig. 37.1). It is separated from the underlying stroma by an apparent basement membrane. Superior to this is a layer of basal cells from which the other cell layers differentiate. Above the basal layer are five or six layers of parabasal cells. Above these are intermediate and superficial cell layers. The intermediate cell layer consists of large cells, each with reticulated nuclei and vacuoles of glycogen in the cytoplasm. The superficial cell layer varies in thickness, depending on the oestradiol : progesterone ratio. The superficial cells are flattened and have small nuclei, the cytoplasm containing glycogen (Fig. 37.2). A small amount of keratin is produced in some of the cells, which becomes ‘cornified’. During the reproductive years the superficial cells are constantly shed or exfoliated into the vagina, and differentiation of cells from the basal layer also proceeds constantly.

The characteristics of the superficial cells can be studied by taking a smear from the cervix and staining it with Papanicolaou’s stain. In some women the nuclei become abnormally shaped or dyskaryotic, which may indicate a precancerous change; this can be detected by cervical smears.

Cervical exfoliative cytology

The development of cervical carcinoma is preceded by the appearance of abnormal (dyskaryotic) cervical cells. These can be detected by microscopically examining an exfoliative cervical smear, stained using the Papanicolaou stain (the Pap test). As this is a screening test false negatives may occur, estimated at 5–15%. The proportion of false-negative smears will be reduced if strict criteria are adopted for taking and for examining the smear.

A further refinement is liquid-based cytology that involves taking cervical cells with a Cervex sampler brush and rinsing the brush into a vial of fixative. The cells are not obscured by blood or mucus and are all fixed properly. In the laboratory, a monolayer of cells is made which is easier to interpret. If the result is inconclusive, the remaining cells in the vial can be used to make a hybrid capture test, which will detect the presence of oncogenic HPV. This methodology reduces the unsatisfactory/inconclusive smear rate by 80% and has been shown to be cost-effective. A further advantage of this test is that it is likely to reduce the number of colposcopies that gynaecologists make when an inconclusive Pap smear abnormality is found. The technique has the potential to be used for the detection of other sexually transmitted diseases, such as chlamydia and gonorrhoea.

The recommended smear regimen is summarised in Box 37.1. In women aged 30 and over, the doctor or nurse taking the smear should also examine the woman’s breasts, teach her breast self-examination, and after the age of 40 measure her blood pressure.

REPORTING ON SMEARS

Cytologists have agreed that nuclear abnormalities should form the basis of a cytological diagnosis. They have agreed to report smears as follows:

New cervical screening techniques

Meta-analysis of conventional screening found a sensitivity of 58%, a specificity of 69% and a false-negative rate of 20%. This has led to the exploration of other technologies to improve diagnostic accuracy. In the ThinPrep method, the sample is placed into a 20 mL vial of buffered alcohol, which is then prepared for automated image analysis. A study by Duke University and the American Association of Obstetrics and Gynaecology reported that this technique was cost-effective and would reduce cancer cases, deaths and serious interventions, including hysterectomy, by 57% if screening was performed every 2 years.

Detection of HPV in women:

HPV-negative women should have repeat cervical cytology at recommended intervals. HPV-positive women should be offered colposcopic evaluation.